Depletion of mitochondrial protease OMA1 alters proliferative properties and promotes metastatic growth of breast cancer cells

Amita Daverey, Roman M. Levytskyy, Kimberly M. Stanke, Martonio Ponte Viana, Samantha Swenson, Stephen L. Hayward, Madhusudhanan Narasimhan, Oleh Khalimonchuk, Srivatsan Kidambi

Research output: Contribution to journalArticle

Abstract

Metastatic competence of cancer cells is influenced by many factors including metabolic alterations and changes in mitochondrial biogenesis and protein homeostasis. While it is generally accepted that mitochondria play important roles in tumorigenesis, the respective molecular events that regulate aberrant cancer cell proliferation remain to be clarified. Therefore, understanding the mechanisms underlying the role of mitochondria in cancer progression has potential implications in the development of new therapeutic strategies. We show that low expression of mitochondrial quality control protease OMA1 correlates with poor overall survival in breast cancer patients. Silencing OMA1 in vitro in patient-derived metastatic breast cancer cells isolated from the metastatic pleural effusion and atypical ductal hyperplasia mammary tumor specimens (21MT-1 and 21PT) enhances the formation of filopodia, increases cell proliferation (Ki67 expression), and induces epithelial-mesenchymal transition (EMT). Mechanistically, loss of OMA1 results in alterations in the mitochondrial protein homeostasis, as reflected by enhanced expression of canonic mitochondrial unfolded protein response genes. These changes significantly increase migratory properties in metastatic breast cancer cells, indicating that OMA1 plays a critical role in suppressing metastatic competence of breast tumors. Interestingly, these results were not observed in OMA1-depleted non-tumorigenic MCF10A mammary epithelial cells. This newly identified reduced activity/levels of OMA1 provides insights into the mechanisms leading to breast cancer development, promoting malignant progression of cancer cells and unfavorable clinical outcomes, which may represent possible prognostic markers and therapeutic targets for breast cancer treatment.

Original languageEnglish (US)
Article number14746
JournalScientific reports
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

Peptide Hydrolases
Breast Neoplasms
Growth
Mitochondrial Proteins
Mental Competency
Neoplasms
Mitochondria
Homeostasis
Cell Proliferation
Unfolded Protein Response
Pseudopodia
Carcinoma, Intraductal, Noninfiltrating
Epithelial-Mesenchymal Transition
Organelle Biogenesis
Pleural Effusion
Quality Control
Carcinogenesis
Breast
Therapeutics
Epithelial Cells

ASJC Scopus subject areas

  • General

Cite this

Depletion of mitochondrial protease OMA1 alters proliferative properties and promotes metastatic growth of breast cancer cells. / Daverey, Amita; Levytskyy, Roman M.; Stanke, Kimberly M.; Viana, Martonio Ponte; Swenson, Samantha; Hayward, Stephen L.; Narasimhan, Madhusudhanan; Khalimonchuk, Oleh; Kidambi, Srivatsan.

In: Scientific reports, Vol. 9, No. 1, 14746, 01.12.2019.

Research output: Contribution to journalArticle

Daverey, Amita ; Levytskyy, Roman M. ; Stanke, Kimberly M. ; Viana, Martonio Ponte ; Swenson, Samantha ; Hayward, Stephen L. ; Narasimhan, Madhusudhanan ; Khalimonchuk, Oleh ; Kidambi, Srivatsan. / Depletion of mitochondrial protease OMA1 alters proliferative properties and promotes metastatic growth of breast cancer cells. In: Scientific reports. 2019 ; Vol. 9, No. 1.
@article{933dfffa47774616a9447c6ef2b68528,
title = "Depletion of mitochondrial protease OMA1 alters proliferative properties and promotes metastatic growth of breast cancer cells",
abstract = "Metastatic competence of cancer cells is influenced by many factors including metabolic alterations and changes in mitochondrial biogenesis and protein homeostasis. While it is generally accepted that mitochondria play important roles in tumorigenesis, the respective molecular events that regulate aberrant cancer cell proliferation remain to be clarified. Therefore, understanding the mechanisms underlying the role of mitochondria in cancer progression has potential implications in the development of new therapeutic strategies. We show that low expression of mitochondrial quality control protease OMA1 correlates with poor overall survival in breast cancer patients. Silencing OMA1 in vitro in patient-derived metastatic breast cancer cells isolated from the metastatic pleural effusion and atypical ductal hyperplasia mammary tumor specimens (21MT-1 and 21PT) enhances the formation of filopodia, increases cell proliferation (Ki67 expression), and induces epithelial-mesenchymal transition (EMT). Mechanistically, loss of OMA1 results in alterations in the mitochondrial protein homeostasis, as reflected by enhanced expression of canonic mitochondrial unfolded protein response genes. These changes significantly increase migratory properties in metastatic breast cancer cells, indicating that OMA1 plays a critical role in suppressing metastatic competence of breast tumors. Interestingly, these results were not observed in OMA1-depleted non-tumorigenic MCF10A mammary epithelial cells. This newly identified reduced activity/levels of OMA1 provides insights into the mechanisms leading to breast cancer development, promoting malignant progression of cancer cells and unfavorable clinical outcomes, which may represent possible prognostic markers and therapeutic targets for breast cancer treatment.",
author = "Amita Daverey and Levytskyy, {Roman M.} and Stanke, {Kimberly M.} and Viana, {Martonio Ponte} and Samantha Swenson and Hayward, {Stephen L.} and Madhusudhanan Narasimhan and Oleh Khalimonchuk and Srivatsan Kidambi",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-49327-2",
language = "English (US)",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Depletion of mitochondrial protease OMA1 alters proliferative properties and promotes metastatic growth of breast cancer cells

AU - Daverey, Amita

AU - Levytskyy, Roman M.

AU - Stanke, Kimberly M.

AU - Viana, Martonio Ponte

AU - Swenson, Samantha

AU - Hayward, Stephen L.

AU - Narasimhan, Madhusudhanan

AU - Khalimonchuk, Oleh

AU - Kidambi, Srivatsan

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Metastatic competence of cancer cells is influenced by many factors including metabolic alterations and changes in mitochondrial biogenesis and protein homeostasis. While it is generally accepted that mitochondria play important roles in tumorigenesis, the respective molecular events that regulate aberrant cancer cell proliferation remain to be clarified. Therefore, understanding the mechanisms underlying the role of mitochondria in cancer progression has potential implications in the development of new therapeutic strategies. We show that low expression of mitochondrial quality control protease OMA1 correlates with poor overall survival in breast cancer patients. Silencing OMA1 in vitro in patient-derived metastatic breast cancer cells isolated from the metastatic pleural effusion and atypical ductal hyperplasia mammary tumor specimens (21MT-1 and 21PT) enhances the formation of filopodia, increases cell proliferation (Ki67 expression), and induces epithelial-mesenchymal transition (EMT). Mechanistically, loss of OMA1 results in alterations in the mitochondrial protein homeostasis, as reflected by enhanced expression of canonic mitochondrial unfolded protein response genes. These changes significantly increase migratory properties in metastatic breast cancer cells, indicating that OMA1 plays a critical role in suppressing metastatic competence of breast tumors. Interestingly, these results were not observed in OMA1-depleted non-tumorigenic MCF10A mammary epithelial cells. This newly identified reduced activity/levels of OMA1 provides insights into the mechanisms leading to breast cancer development, promoting malignant progression of cancer cells and unfavorable clinical outcomes, which may represent possible prognostic markers and therapeutic targets for breast cancer treatment.

AB - Metastatic competence of cancer cells is influenced by many factors including metabolic alterations and changes in mitochondrial biogenesis and protein homeostasis. While it is generally accepted that mitochondria play important roles in tumorigenesis, the respective molecular events that regulate aberrant cancer cell proliferation remain to be clarified. Therefore, understanding the mechanisms underlying the role of mitochondria in cancer progression has potential implications in the development of new therapeutic strategies. We show that low expression of mitochondrial quality control protease OMA1 correlates with poor overall survival in breast cancer patients. Silencing OMA1 in vitro in patient-derived metastatic breast cancer cells isolated from the metastatic pleural effusion and atypical ductal hyperplasia mammary tumor specimens (21MT-1 and 21PT) enhances the formation of filopodia, increases cell proliferation (Ki67 expression), and induces epithelial-mesenchymal transition (EMT). Mechanistically, loss of OMA1 results in alterations in the mitochondrial protein homeostasis, as reflected by enhanced expression of canonic mitochondrial unfolded protein response genes. These changes significantly increase migratory properties in metastatic breast cancer cells, indicating that OMA1 plays a critical role in suppressing metastatic competence of breast tumors. Interestingly, these results were not observed in OMA1-depleted non-tumorigenic MCF10A mammary epithelial cells. This newly identified reduced activity/levels of OMA1 provides insights into the mechanisms leading to breast cancer development, promoting malignant progression of cancer cells and unfavorable clinical outcomes, which may represent possible prognostic markers and therapeutic targets for breast cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=85073177504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073177504&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-49327-2

DO - 10.1038/s41598-019-49327-2

M3 - Article

C2 - 31611601

AN - SCOPUS:85073177504

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 14746

ER -